Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (December 2025)
21 slides from Syngene International's investor presentation, Dec 17, 2025
Slide 1: Stock exchange cover letter: Investor Presentation
Ref: Syn/CS/SE/IP/2025-26/Dec/06 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 9191 CIN: L85110KA1993PLC014937 www.syngeneintl.com December 17, 2025 To, To, B The Manag
Slide 2: Webinar on Clinical Trials Market
Webinar on Clinical Trials Market - By Dr. Mrinal Kammili 17 Dec 2025
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Agenda
Agenda Sr. no Timing Particulars Led by Why this webinar 1 1:30 - 1:40 PM Nandini Agarwal Introduction to our inhouse expert - Dr. Mrinal Kammili • Clinical Trials Industry 2 1:40 PM - 2:20 PM Dr. Mrinal Kammili • Overview of Syngene’s Translation and Clinical Research (T&CR) business 3 2:20 PM - 2:
Slide 5: Why this webinar
Why this webinar • In Q2 FY26, Syngene announced a deal for first global phase III clinical trial from a U.S.-based biotech company. • The trial will recruit patients across clinical sites in India and the U.S., reflecting Syngene’s growing capabilities in the global clinical trials market • We got
Slide 6: Our in-house expert for the webinar – Dr. Mrinal Kammili
Our in-house expert for the webinar – Dr. Mrinal Kammili • Joined Syngene in January 2025 – part of the Syngene Executive Committee • Head of Translational & Clinical Research with over 27 years of experience in clinical research • A medical doctor and AHA-certified intensivist • Previously worked a
Slide 7: Clinical Trials Market
Clinical Trials Market Putting Science to Work Putting Science to Work
Slide 8: Translational and Clinical Research forms a large and growing segment within the overall global CRDMO market
Translational and Clinical Research forms a large and growing segment within the overall global CRDMO market Global CRDMO market expected to grow at ~9% CAGR Key growth drivers of Clinical CRO market Overall CRDMO Market Size (USD Bn) Increasing R&D Pipeline: growing at ~7% CAGR; new drugs require 3
Slide 9: Market Outlook – Rapid growth in APAC and India market driven by strong tail winds
Market Outlook – Rapid growth in APAC and India market driven by strong tail winds APAC leads growth; North America still dominates with ~30% of the global clinical CRO market Level of attractiveness - Indian CRO market Factor Level of attractiveness Future impact 5-yr CAGR LOW High North America re
Slide 10: Indian market is fragmented and players with differentiated capabilities have an edge
Indian market is fragmented and players with differentiated capabilities and strong regulatory data management experience have an edge Global Clinical CRO players Key Success Factors The Indian market is relatively fragmented in comparison to the global Caribbean clinical CRO industry which has larg
Slide 11: Translational and Clinical Research forms an integral part of the drug discovery and development value chain
Translational and Clinical Research forms an integral part of the overall drug discovery and development value chain Discovery Development Commercialization A Target Lead Pre-Clinical Translational Research Product Launch Identification Generation B C D NDA Lead Animal Phase I Phase II Phase III Fil
Slide 12: Translational Science: anticipate uncertainty and de-risk before programme reaches the clinic
Translational Science: anticipate uncertainty and de-risk before programme reaches the clinic Basic Preclinical Translational Clinical Research Discovery Development Trial Past View Today Translational science was seen as a handoff point Translating It’s the foundation for planning, resourcing, and
Slide 13: Pillars of translational sciences at Syngene
Pillars of translational sciences at Syngene Pillars of translational sciences Clinical Translational AI-driven Biobanking biomarkers Models precision (Organoids) medicine Platform development Putting Science to Work 12
Slide 14: Patient based Clinical Trial
Patient based Clinical Trial Protocol Development, Regulatory Clinical Study Report Dossier development, Submission & Writing follow up (IND/SEC meetings) Biometrics & Clinical Data Management Trial management and Study Monitoring Clinical Trial Central Lab services Clinical Supplies Management Putt
Slide 15: Syngene's T&CR business
Syngene’s T&CR business Putting Science to Work Putting Science to Work
Slide 16: Syngene's T&CR business is now a segment within our Research business
Syngene’s T&CR business is now a segment within our Research business What does T&CR business include Syngene Strengths Human Pharmacology Unit – Healthy volunteer early-phase BA/BE Track Record and Expertise: Completed 800 BA/BE studies for studies, drug-drug interaction studies, food effect studie
Slide 17: T&CR: Part of our diversified platform encompassing Research Services, LM CDMO and SM CDMO
T&CR: Part of our diversified platform encompassing Research Services, LM CDMO and SM CDMO Research Services (CRO) Discovery Services Large Molecule CDMO Small Molecule CDMO Dedicated R&D Centers T&CR Flexible Platform with capability Ring-fenced infrastructure for Comprehensive research services Pr
Slide 18: Operating models in T&CR
Operating models in T&CR 2 way Model 3 way Model Syngene + Client + Partner collaboration for Direct Syngene-client engagement global reach End-to-end clinical trial solutions Shared responsibilities for large scale multi region trials with diverse population subsets The revenue is milestone based w
Slide 19: Strategic focus for the T&CR business
Strategic focus for the T&CR business Support more complex and new modalities clinical trials 3S formula – strengthen, stabilize and streamline the existing functions and portfolio in near term Forward integration into subsequent phases of clinical trials in mid to long term Accelerated Decisions, R
Slide 20: Summary
Summary • T&CR enables better support decisions across the drug development lifecycle, connecting discovery sciences and T&CR part of clinical services Research Services • Foundation for planning, resourcing, and executing drug development from the earliest stages Big and growing • Clinical Trials f
Slide 21: Q&A
Q&A • Q&A focused on T&CR industry, business/operating model, better understanding of Syngene offerings in the segment • We will not be to disclose any Syngene specific financials at this point of time Putting Science to Work Putting Science to Work
Syngene International — Investor Presentation (December 2025) on 6ix